UNSPSC 51272405: Fomocaine

This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4XO7A09HQM. European Medicines Agency schedules Fomocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07779MIG. Fomocaine generally arises in the molecular formula C20H25NO2.

The term FOMOCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) FOMOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fomocaine under HS 29349990 and SITC 51579. As of Q4 2014, FOMOCAINE remains the US FDA Preferred Term for this commodity. Fomocaine bears US NLM identifiers UMLS ID C0060629 and NCI Concept Code C65747. SMILES: O1CCN(CCCC2CCC(CC2)COC2CCCCC2)CC1.

UNSPSC 51272405 Fomocaine, a Commodity code, does not appear in recent state and local procurement activity. The three most recent opportunities tagged under this code—Seminole County's purchase of naloxone and drug deactivation systems, Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer pharmacy programs, and Minnesota's multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products—involve naloxone, pharmacy benefit management, and generic drug distribution respectively, none of which align with fomocaine's scope as a local anesthetic. The mismatch suggests either miscoding by issuing bodies or limited current procurement activity under the commodity code itself.

No state or local government solicitations for fomocaine as a standalone product or service line appear in the recent opportunities block. Without verifiable recent demand under this specific code, pursuing opportunities here carries execution risk; the coded opportunities that do appear are unrelated to fomocaine procurement, making the code an unreliable signal for business development in this category at present.